Can Medicaid Reimbursement Help Give Female Condoms a Second Chance in the United States? by Witte, Susan S. et al.
Can Medicaid Reimbursement Help Give Female Condoms
a Second Chance in the United States?
The female condom is the
only other barrier contracep-
tion method besides the
male condom, and it is the
only ‘‘woman-initiated’’ de-
vice for prevention of sexu-
ally transmitted infections.
Although studies demon-
strate high acceptability and
effectiveness for this device,
overall use in the United
States remains low.
The female condom has
beenavailable throughMed-
icaid in many states since
1994. We provide the first
published summary of data
on Medicaid reimbursement
for the female condom. Our
findings demonstrate low
rates of claims for female
condoms but high rates of
reimbursement.
In light of the 2009 ap-
proval of a new, cheaper
female condom and the re-
cent passage of comprehen-
sive health care reform, we
call for research examining
how health care providers
can best promote consumer
use of Medicaid reimburse-
ment to obtain this im-
portant infection-prevention
device. (Am J Public Health.
2010;100:1835–1840. doi:10.
2105/AJPH.2009.179598)
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THE FEMALE CONDOM IS THE
only other barrier contraception
method other than the male con-
dom, and it is the only ‘‘woman-
initiated’’ device for prevention of
sexually transmitted infections
(STIs), including HIV. Male and
female condoms are currently the
only technologies that may pro-
vide protection against both preg-
nancy and STIs. Studies have
demonstrated that the female
condom’s effectiveness in pre-
venting pregnancy1 and STIs2 is
comparable to that of the male
condom. Studies have also shown
that STI prevention counseling
that addresses both male and fe-
male condoms results in more
condom use than does counseling
that addresses male condoms
alone.3 Although the device is
used predominantly by women, it
is also increasingly used by men to
have anal sex with men, despite
lack of Food and Drug Adminis-
tration (FDA) approval for such
use.4 Acceptability and effective-
ness studies consistently demon-
strate that women at risk of STIs
do use the device when it is avail-
able but that levels of use in the
United States remain low.5 Several
reports suggest there is a lack of
leadership-level commitment to
ensure improved distribution of
the device in the public health care
system.5–7
The female condom has been
a reimbursable over-the-counter
device for Medicaid recipients in
many US states for more than
a decade. Medicaid is the largest
provider of reproductive health
care among low-income people in
the United States, and low-income
women represent a disproportion-
ately large proportion of those
newly diagnosed with HIV infec-
tions.8–10 A significant proportion
of HIV-infected Medicaid benefi-
ciaries are women, and more than
60% of women living with HIV in
the United States receive Medic-
aid.11–13 Because the evolving HIV
epidemic in the United States
increasingly affects women, mi-
norities, persons infected through
heterosexual contact, and the
poor,10 access to the female con-
dom through Medicaid may rep-
resent a critical STI prevention
policy for poor women in the
United States.
Given the low profile of the
female condom in the commercial
sphere, we sought to document
reimbursement for the female
condom through Medicaid. We
asked Medicaid representatives in
each state about requests for fe-
male condoms and reimbursement
for female condoms in response to
those requests. Our goals were to
provide a snapshot of female con-
dom utilization through Medicaid
and to inform a renewed dialogue
about the device and its role in HIV
prevention.
METHODS
In 2002, Female Health Com-
pany—the manufacturer of the
only FDA-approved female
condom—published on its Web
site a list of contacts at state Med-
icaid programs in 40 states that
were said to offer Medicaid re-
imbursement for the female
condom. We began data collec-
tion by contacting those indi-
viduals. For the 10 states not on
the manufacturer’s 2002 list,
we called the main number of
each state’s Medicaid office. Thus,
the sample included all 50 states.
We sought to collect the fol-
lowing data: number of claims
for reimbursement, number of
units for which reimbursement
was issued, total amount billed to
the state Medicaid program, and
total amount paid out by the
program. We requested data for
the period from 1997 through
2007. For consistency, we fol-
lowed a script when making all
data requests. At most state
Medicaid programs, we had to
make a series of contacts before
we reached a staff member who
could access data on reimburse-
ment for female condoms. When
a given contact was unable to
provide the data we needed, we
asked that contact to recommend
the next person to whom we
should direct our inquiry. Con-
tact attempts continued until we
obtained data, were told that the
data could not or would not be
provided, were told that the data
would require payment, or were
told that the state did not reim-
burse for the female condom.
Data were collected from 2007
through 2009.
RESULTS
Figure 1 illustrates each state’s
reimbursement status and
whether data were provided to
researchers. Thirty-two states
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(64%) provided reimbursement;
18 states (36%) did not. Of those
providing reimbursement, 29
(91%) provided data. A dispro-
portionate number of nonreim-
bursing states are in the south-
east.
Table 1 shows data from the
29 states that provided it, illus-
trating vast differences in reim-
bursement, claims, and reporting
across those states. By far the
highest numbers of female con-
doms were reimbursed in Cali-
fornia, Illinois, Massachusetts,
Michigan, New York, Texas, and
Washington. Although some
states provided thorough and
comprehensive data across the
10-year period, others (e.g.,
Alaska) provided data for only
one or two years. Some states
(e.g., Massachusetts, Maryland)
provided information about the
number of female condom units
distributed in response to claims
made through Medicaid, but
not about the number of claims
submitted. Although some states
had thousands of claims, many
had few or none at all. Some
states reimbursed hundreds of
thousands of dollars per year,
whereas others reimbursed less
than $10 annually. Only three
states—Iowa, Michigan, and
Nevada—demonstrated steady
increases in female condom
reimbursement. The trend in
most states was toward decreas-
ing numbers of claims and units.
Some of the states that did not
reimburse for the device through
Medicaid (e.g., Kansas) reported
that they received claims for re-
imbursement.
DISCUSSION
From the perspective of pre-
vention advocacy, the good news
is that policy appears to have
been working in many states:
claims were being made for
Medicaid reimbursement for fe-
male condoms. The bad news is
that levels of utilization of this
efficacious STI barrier device
appear to have been uneven
across states and very low in
most states. Our findings raise
many questions: Is the Medi-
caid reimbursement program
underutilized? Or does Medicaid
reimbursement activity simply
provide a parallel to activity in
commercial markets, suggesting
that there is no market for the
device? If Medicaid reimburse-
ment is underutilized, how can
we promote awareness of the
device among health care pro-
viders who can write fiscal orders
through Medicaid and can dis-
pense the device to individuals
at risk for STIs?
FIGURE 1—State Medicaid program reimbursement for the female condom and provision of reimbursement data to researchers: United States,
2007–2009.
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High-volume reimbursement
activity in a state appears to
be correlated with a high pre-
valence of AIDS cases. Five
of the high-volume states in
the current study (New York,
California, Texas, Illinois, and
Massachusetts) are among the 10
states with the highest AIDS
prevalence.14 Is high volume in
some states attributable to state
or local initiatives promoting the
device (e.g., the New York State
Condom and New York City
Condom programs),15 or is it
caused by individual interest in
the device? Are claims submitted
only by women, or do some of
these claims represent male
users?
Latka16 reminded us that up-
take of reproductive health de-
vices can take considerable time.
In this case, however, time spent
on uptake may result in thou-
sands of infections that could be
averted and lives that might be
saved if the female condom were
more visible, more accessible,
and more effectively promoted
as an alternative to the male
condom.
Lack of Support and
Ignorance as Barriers
Barriers to use of the female
condom have been well-docu-
mented, including lack of con-
sumer satisfaction with the
device,17 lack of consumer
awareness of the device,18,19
and lack of access to the device,20
but there does not seem to have
been much of an attempt to
overcome these obstacles. Nev-
ertheless, the device enjoys rela-
tively high acceptability rates
that range from 37% to
96%.17,20 Mantell et al.19 and
Kaler18 noted that there is a lack
of support for the female condom
among reproductive health pro-
viders, in terms of providers’
TABLE 1—Claims and Reimbursements for Female Condoms Among the 32 State Medicaid Programs









Alaska: 2005 1 1 . . . 2.55
Arizona
2006 6 6 . . . 8.19
2005 7 7 . . . 14.08
2004 20 18 . . . 16.90
Arkansas: 1997–2007 0 0 0.00 0.00
Californiaa
2003–2007 . . . . . . . . . . . .
2002 586 20 161 . . . 53 554.38
2001 3 979 149 846 . . . 386 117.49
Florida
2007 1 3 . . . 11.69
2006 1 3 . . . 11.69
2005 0 0 . . . . . .
2004 1 6 . . . 16.91
2003 5 30 . . . 84.55
Hawaii:b 1997–2007 . . . . . . . . . . . .
Illinois
2007 990 928 . . . 50 433.47
2006 1 022 954 . . . 43 219.50
2005 947 913 . . . 31 730.86
2004 795 763 . . . 26 832.98
2003 1 517 1 446 . . . 36 889.43
2002 2 461 2 346 . . . 62 335.58
2001 1 940 1 873 . . . 75 006.29
2000 1 896 1 838 . . . 106 259.55
1999 2 266 2 180 . . . 126 826.61
1998 2 088 2 005 . . . 117 506.20
1997 2 589 2 487 . . . 116 306.54
Indiana
2005 2 2 . . . 44.00
2004 2 1 . . . 3.00
2003 2 1 . . . 3.00
Iowa
2007 98 945 . . . 283.50
2006 110 940 . . . 275.57
2005 54 592 . . . 166.65
2004 46 620 . . . 173.60
2003 9 132 . . . 36.78
Louisiana
2007 0 0 0.00 0.00
2006 1 1 . . . 3.61
2005 0 0 0.00 0.00
2004 1 12 . . . 8.97
1997–2003 0 0 0.00 0.00
Continued
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willingness to promote the use
of the device. Kaler indicated
that successful uptake of the de-
vice will not be achieved in
North America without better
advocacy and promotion from
key stakeholders.18 Hoffman
et al.20 summarized accessibility
barriers in the United States, in-
cluding ridicule in the press,
limited promotion, high cost,
and inadequate training of pro-
viders.
Few of the contacts we spoke to
during our study were even aware
that the device existed. Some
contacts responded to our re-
quests with amusement, confu-
sion, resistance, or annoyance. A
common first response was, ‘‘The
female what?’’ It took many
months, and in some cases a dozen
or more contacts at a given pro-
gram, to collect the data we
sought. In such a climate, what
would it take to convince key
stakeholders to support the device
consistently?
In 2009, the FDA granted
market approval to the FC2, Fe-
male Health Company’s second-
generation female condom. The
FC2 is significantly less expen-
sive to manufacture and less ex-
pensive to the consumer than is
its predecessor. One study (not
US based) demonstrated that
a well-designed program pro-
moting female condom use, even
as an alternative to male condom
use, would probably be cost-ef-
fective and would save public-
sector health funds.21 The public
policy priority should be to
identify accessible, affordable,
feasible alternatives for barrier
protection—including the female
condom, which may have been
given a second chance by the
FDA’s approval of the FC2—and
to promote these alternatives to




2007 11 140 . . . 508 685.50
1996–2006 29 371 . . . 1 294 874.59
Massachusetts
2007 . . . 16 . . . 132.32
2006 . . . 10 . . . 115.29
2005 . . . 39 . . . 235.79
2004 . . . 53 . . . 481.18
2003 . . . 93 . . . 1 434.58
2002 . . . 67 . . . 732.47
2001 . . . 107 . . . 1 022.00
2000 . . . 125 . . . 1 010.27
1999 . . . 141 . . . 1 078.88
1998 . . . 73 . . . 867.59
Michigan
2007 224 2 798 . . . 1 986.58
2006 180 2 438 . . . 1 145.86
2005 147 1 607 . . . 755.29
2004 141 1 384 . . . 622.80
2003 102 908 . . . 871.68
Minnesota
2007 587 7 097 . . . 828.47
2006 1 078 13 169 . . . 905.55
2005 1 165 15 309 . . . 610.27
2004 982 13 615 . . . 616.80
Montana
2007 2 8 12.00 12.00
2006 1 1 1.50 1.50
2005 0 0 0.00 0.00
2004 2 7 21.00 10.50
2003 1 1 9.75 9.75
Nebraska
2006 1 12 8.39 8.39
2005 1 24 12.78 12.78
2004 2 24 8.40 0.00
Nevada
2006 12 136 . . . 51.68
2005 1 12 . . . 4.56
2004 1 0 0.00 0.00
New Hampshire
2007 12 21 73.50 40.00
2006 88 133 398.94 220.00
2005 90 140 555.10 320.00
2004 64 97 460.08 150.00
2003 6 403 147.94 0.00
New York
2007 1 490 44 206 162 322.99 133 639.63
2006 1 157 25 113 88 716.99 71 350.50
Continued
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Conclusions
We found that the female con-
dom is available to Medicaid ben-
eficiaries in 32 states. Financed
by state governments and the
federal government, Medicaid is
among the largest payers for re-
productive health services in the
United States.8 Under federal law,
Medicaid must cover family plan-
ning services. Most health insur-
ance programs do not provide
adequate coverage for family
planning services.22 The federal
Patient Protection and Affordable
Care Act, signed into law on
March 23, 2010, includes a pro-
vision that will allow 16 million
more Americans to join Medicaid
by 2019, guaranteeing family
planning services (including access
to the female condom) without
cost sharing.23
Our findings provide evidence
that there is some Medicaid re-
imbursement for the female con-
dom, suggesting the need for
a new dialogue about whether
knowledgeable providers can and
should promote use of the newer,
less expensive FC2 female con-
dom. Moreover, there have re-
cently been increasing calls by
scientists, journal editors, mental
health professionals, and health
care providers for more promo-
tion and support of the female
condom,5–7,24 including use of the
device for protection during anal
sex.4
Findings suggest that more re-
search is needed to identify bar-
riers to awareness of the device
and to uptake of the product at the
provider and consumer levels.
There is also a need to examine
why rates of claims for the device
are so uneven across states and to
identify strategies to increase ac-
cess in low-utilization states. In-
creased access to the female con-
dom (assuming that the devices
are used for risk reduction) should
TABLE 1—Continued
2005 1 476 30 302 84 930.37 63 276.94
2004 4 316 102 067 119 843.69 101 067.93
2003 3 057 65 702 78 245.57 68 803.15
2002 746 12 183 36 888.26 30 779.53
2001 755 12 244 35 563.88 26 522.73
2000 768 11 149 32 463.12 22 933.73
1999 1 027 15 664 46 101.14 32 641.64
1998 1 065 16 482 49 478.51 34 734.37
1997 1 002 12 878 37 727.57 27 288.10
North Dakota
2006 2 . . . 6.00 6.00
2005 11 . . . 33.00 27.00
2004 13 . . . 39.00 23.00
Ohioc
2008 . . . 497 . . . 548.94
2007 . . . 525 . . . 2 171.33
2006 . . . 581 . . . 1 688.87
2005 . . . 290 . . . 684.85
2004 . . . 83 . . . 244.35
2003 . . . 5 . . . 84.00
Oklahoma: 2007 1 0 0.00 0.00
Pennsylvania: 2007 . . . 103 . . . 231.75
Texas
2006 31 37 . . . 268.13
2005 192 198 . . . 1 506.34
2004 30 30 . . . 245.78
2003 6 6 . . . 48.00
2002 1 1 . . . 12.00
2001 22 22 . . . 210.00
2000 33 33 . . . 294.00
1999 47 48 . . . 420.00
Utah: 1997–2007 0 0 0.00 0.00
Vermont
2003 2 60 180.00 137.30
2002 0 0 0.00 0.00
2001 2 60 180.00 127.44
Virginia: 2007–2008 0 0 0.00 0.00
Washington
2007 308 991 . . . 3 598.00
2006 317 970 . . . 3 854.00
2005 4 061 8 597 . . . 50 010.00
2004 2 241 4 818 . . . 28 096.00
2003 1 046 2 170 . . . 13 129.00
Wisconsin
2008 5 8 . . . 27.52
2007 68 167 . . . 567.72
2006 124 272 . . . 832.18
2005 62 131 . . . 411.36
Continued
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translate into fewer transmissions
of STIs, including HIV. Use of ef-
fective barrier devices for the pre-
vention of HIV and STI transmis-
sion should be diligently promoted.
Approval of the FC2 and a working
Medicaid reimbursement policy
provide a second chance to make
the female condom a successful
weapon in the war on AIDS. j
About the Authors
At the time of the study, all authors were
with the Social Intervention Group,
Columbia University School of Social
Work, New York, NY.
Correspondence should be sent to Susan S.
Witte, Columbia University School of Social
Work, 1255AmsterdamAve, New York, NY
10027 (e-mail: ssw12@columbia.edu).
Reprints can be ordered at http://www.
ajph.org by clicking the ‘‘Reprints/Eprints’’
link.
This commentary was accepted January
31, 2010.
Contributors
S. S. Witte conceptualized the study,
developed the study protocols,
supervised all aspects of the study,
collected data, and led the writing of the
article. K. Stefano and C. Hawkins
assisted with data collection and with
writing and editing the article.
Acknowledgments
The authors would like to acknowledge
the Medicaid contacts in each state who
were willing to take the time to send us
data, when available.
References
1. Hatcher R, Trussell J, Nelson AL,
Cates W Jr, Steward FH, Kowal D.
Contraceptive Technology. 18th ed. New
York, NY: Ardent Media; 2000.
2. Vijayakumar G, Mabude Z, Smit J,
Beksinska M, Lurie M. A review of female-
condom effectiveness: patterns of use
and impact on protected sex acts and
STI incidence. Int J STD AIDS. 2006;
17(10):652–659.
3. Latka M, Gollub E, French P, Stein
Z. Male-condom and female-condom
use among women after counseling in
a risk-reduction hierarchy for STD pre-
vention. Sex Transm Dis. 2000;27(8):
431–437.
4. Kelvin EA, Smith RA, Mantell JE,
Stein ZA. Adding the female condom to
the public health agenda on prevention of
HIV and other sexually transmitted in-
fections among men and women during
anal intercourse. Am J Public Health.
2009;99(6):985–987.
5. The female condom: still an under-
used prevention tool. Lancet Infect Dis.
2008;8(6):343–343.
6. Hoffman S, Smit JA, Adams-Skinner
J, Exner T, Mantell J, Stein Z. Female
condom promotion needed. Lancet Infect
Dis. 2008;8(6):348.
7. Center for Health and Gender Eq-
uity. Saving Lives Now: Female Condoms
and the Role of US Foreign Aid. Washing-
ton, DC: Center for Health and Gender
Equity; 2008.
8. Henry J. Kaiser Family Foundation.
Medicaid’s Role for Women. Menlo Park,
CA: Henry J. Kaiser Family Foundation;
2007.
9. Aral SO, Wasserheit JN. Interactions
among HIV, other sexually transmitted
diseases, socioeconomic status, and pov-
erty in women. In: O’Leary A, Jemmott
LS, eds. Women at Risk: Issues in the
Primary Prevention of AIDS. New York,
NY: Plenum Press; 1995:1342.
10. Karon JM, Fleming PL, Steketee RW,
De Cock KM. HIV in the United States
at the turn of the century: an epidemic
in transition. Am J Public Health. 2001;
91(7):1060–1068.
11. Henry J. Kaiser Family Foundation.
Financing HIV/AIDS care: a quilt with
many holes. Available at: http://www.
napwa.org/pdf/Financing-HIV-AIDS-
Care-A-Quilt-with-Many-Holes.pdf.
Published May 2004. Accessed Novem-
ber 20, 2009.
12. Henry J. Kaiser Family Foundation.
HIV/AIDS policy fact sheet: Medicaid and
HIV/AIDS. Available at: http://www.
kff.org/hivaids/upload/7172_04.pdf.
Published February 2009. Accessed
November 20, 2009.
13. Kourtis AP, Bansil P, McPheeters M,
Meikle SF, Posner SF, Jamieson DJ. Hos-
pitalizations of pregnant HIV-infected
women in the USA prior to and during the
era of HAART, 1994–2003. AIDS.
2006;20(14):1823–1831.
14. Henry J. Kaiser Family Foundation.
Reported number of AIDS cases, all ages,
cumulative through 2007. Available at:
http://www.statehealthfacts.org/
comparemaptable.jsp?ind = 502&cat =
11. Accessed November 20, 2009.
15. New York State Dept of Health. New
York State Condom (NYSCondom) Pro-
gram. Available at: http://www.health.
state.ny.us/diseases/aids/facts/condoms/
nyscondom.htm. Revised July 2009.
Accessed November 20, 2009.
16. Latka M. Female-initiated barrier
methods for the prevention of STI/HIV:
Where are we now? Where should we
go? J Urban Health. 2001;78(4):571–
580.
17. Young A. The Female Condom: A
Review. Geneva, Switzerland: World
Health Organization; 1997.
18. Kaler A. The female condom in
North America: selling the technology of
‘‘empowerment.’’ J Gend Stud. 2004;13
(2):139–152.
19. Mantell JE, Hoffman S, Weiss E, et al.
The acceptability of the female condom:
perspectives of family planning providers
in New York City, South Africa, and
Nigeria. J Urban Health. 2001;78(4):
658–668.
20. Hoffman S, Mantell J, Exner T, Stein
Z. The future of the female condom. Int
Fam Plan Perspect. 2004;30(3):139–
145.
21. Marseille E, Kahn JG, Billinghurst K,
Saba J. Cost-effectiveness of the female
condom in preventing HIV and STDs in
commercial sex workers in rural South
Africa. Soc Sci Med. 2001;52(1):135–
148.
22. Gold RB. Family planning and health
care reform: the benefits and challenges
of prioritizing prevention. Guttmacher
Policy Rev. 2009;12:1–7.
23. Guttmacher Institute. The new
health care reform legislation: pros and
cons for reproductive health. Available at:
http://www.guttmacher.org/media/
inthenews/2010/03/29/index.html.
Published March 29, 2010. Accessed
May 22, 2010.
24. Morris K. Greater interest and in-
vestment in female condoms needed.
Lancet Infect Dis. 2008;8(6):351.
TABLE 1—Continued
2004 40 94 . . . 285.08
2003 3 5 . . . 17.20
2002 0 0 . . . 0.00
2001 0 0 . . . 0.00
2000 0 0 . . . 0.00
Note. Ellipses indicate that data were missing.
aCalifornia would not provide data for 2003–2007 without charging a fee.
bHawaii confirmed that they reimburse for the female condom, but did not provide data.
cThe number of claims for Ohio includes both fee-for-service and managed care, but the dollar amount billed pertains only to fee-for-service
claims.
COMMENTARIES
1840 | Commentaries | Peer Reviewed | Witte et al. American Journal of Public Health | October 2010, Vol 100, No. 10
